FDA
-
-
-
-
-
-
-
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
-
-
-
-
-
-
-
Lipella Pharmaceuticals (LIPO) Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
-
-
-
-
-
-
-
Lipella Pharmaceuticals (LIPO) Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
-
-
-
-
-
-
-
Lipella Pharmaceuticals (LIPO) Announces FDA Type C Meeting for LP-10
-
-
-
-
-
-
-
Lipella Pharmaceuticals (LIPO) Granted FDA Orphan Designation for LP-310
-
-
-
-
-
-
-
Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
-
-
-
-
-
-
-
Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

